Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility

Table 1 Characteristics of the patients and controls n (%)

Characteristic	PDAC	pNET	IPMN	Controls
Total number	85	51	19	98
Mean age (yr)	59.12	56.31	57.91	58.9
Gender
Male	51 (60)	20 (39.2)	11 (57.9)	74 (75.5)
Female	34 (40)	31 (60.8)	8 (42.1)	24 (24.5)
Tumor stage
I	13 (15.3)
II	36 (42.4)
III	33 (38.8)
IV	3 (3.5)
G stage
G1		35 (68.6)
G2		14 (27.5)
G3		2 (3.9)
Tumor location
Head	64 (75.3)	19 (37.3)	7 (36.8)
Body and tail	21 (24.7)	32 (62.7)	12 (63.2)
Differentiation status
Well	10 (11.8)
Moderate	39 (45.9)
Poor	36 (42.3)

pNET: Pancreatic neuroendocrine tumor; PDAC: Pancreatic adenocarcinoma; IPMN: Intraductal papillary mucinous neoplasm.

Table 2 Genotype and allele frequencies of the interleukin 1β -511 C/T and +3954 C/T polymorphisms in pancreatic adenocarcinoma, pancreatic neuroendocrine tumor and intraductal papillary mucinous neoplasm patients and controls

	Controls (n = 98)	PDAC (n = 85)	P; OR (95%CI)	pNET (n = 51)	P; OR (95%CI)	IPMN (n = 19)	P; OR (95%CI)
-511 C/T
CC	44	35	1	13	1	6	1
CT	47	44	0.64; 1.18 (0.64-2.16)	31	0.04; 2.23 (1.04-4.81)	10	0.59; 1.56 (0.52-4.65)
TT	7	6	1; 1.08 (0.33-3.49)	7	0.04; 3.95 (1.13-13.84)	3	0.16; 3.14 (0.64-15.56)
CT + TT	54	50	0.37; 1.36 (0.75-2.44)	38	0.02; 2.38 (1.13-5.02)	13	0.32; 1.76 (0.62-5.03)
C allele	135	114	1	57	1	22	1
T allele	61	56	0.74; 1.09 (0.7-1.69)	45	0.03; 1.75 (1.07-2.86)	16	0.19; 1.61 (0.79-3.28)
+3954 C/T
CC	45	50	1	33	1	8	1
CT	44	28	0.08; 0.57 (0.31-1.07)	16	0.07; 0.49 (0.24-1.03)	10	0.79; 1.28 (0.46-3.54)
TT	9	7	0.59; 0.7 (0.24-2.04)	2	0.19; 0.3 (0.06-1.49)	1	1; 0.62 (0.07-5.64)
CT + TT	53	35	0.1; 0.59 (0.33-1.07)	18	0.04; 0.46 (0.23-0.93)	11	0.81; 1.18 (0.43-3.15)
C allele	134	128	1	82	1	26	1
T allele	62	42	0.16; 0.71 (0.45-1.12)	20	0.03; 0.53 (0.29-0.94)	12	0.85; 1.07 (0.51-2.25)

pNET: Pancreatic neuroendocrine tumor; PDAC: Pancreatic adenocarcinoma; IPMN: Intraductal papillary mucinous neoplasm.